Supernus Pharmaceuticals Inc. (SUPN) Business Metric Overview - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Supernus Pharmaceuticals ...

    NASDAQ: SUPN · Real-Time Price · USD
    45.43
    0.50 (1.11%)
    At close: Sep 04, 2025, 3:59 PM
    45.43
    0.00%
    After-hours: Sep 04, 2025, 04:10 PM EDT

    Supernus Pharmaceuticals Revenue Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Mar 31, 2019 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
    APOKYN Revenue 12.82M 14.98M 37.41M 19.87M 17.3M 16.65M 18.76M 21.51M 17.61M 17.21M 18.15M 18.26M 20.45M 18.45M 25.89M 24.63M 26.98M 21.73M 31.21M 34.48M 8.6M 23.94M 22.68M 100.03M 19.41M 20.39M 20.56M 18.57M
    APOKYN Revenue Growth -14.40% -59.97% +88.30% +14.87% +3.88% -11.25% -12.79% +22.18% +2.30% -5.18% -0.61% -10.69% +10.84% -28.76% +5.15% -8.72% +24.16% -30.38% -9.48% +300.95% -64.08% +5.53% -77.32% +415.48% -4.84% -0.79% +10.72% n/a
    GOCOVRI Revenue 36.66M 30.69M 68.61M 35.66M 31.7M 26.56M 31.99M 32.89M 28.75M 26.01M 29.24M 27.88M 24.7M 22.6M 28.59M 29.73M 25.02M 27.37M 22.74M 28.36M 23.68M 92.49M 97.91M n/a 83.1M 100.23M 97.03M 89.12M
    GOCOVRI Revenue Growth +19.46% -55.27% +92.40% +12.47% +19.35% -16.96% -2.74% +14.39% +10.54% -11.05% +4.89% +12.87% +9.29% -20.94% -3.83% +18.81% -8.58% +20.35% -19.82% +19.78% -74.40% -5.53% n/a n/a -17.09% +3.29% +8.88% n/a
    Manufactured Product, Other Revenue 6.53M 8.58M 14.5M 7.3M 7.54M 7.21M 8.27M 7.25M 7.88M 7.87M 8.25M 8.13M 7.65M 7.78M 154.96M 145.53M 138.63M 128.38M 140.74M 152.13M 123.98M n/a 75.22M n/a n/a n/a n/a n/a
    Manufactured Product, Other Revenue Growth -23.84% -40.83% +98.71% -3.27% +4.56% -12.80% +14.03% -7.98% +0.19% -4.66% +1.50% +6.26% -1.62% -94.98% +6.48% +4.98% +7.98% -8.78% -7.49% +22.70% n/a n/a n/a n/a n/a n/a n/a n/a
    Oxtellar X R Revenue 11.64M 10.2M 42.72M 29.8M 29.52M 26.94M 31.05M 29.64M 23.8M 28.91M 27.34M 30.53M 29.96M 27.52M 7.19M 2.37M 315K 71.82M 78.51M 82.91M 89.67M n/a n/a n/a n/a n/a n/a n/a
    Oxtellar X R Revenue Growth +14.11% -76.13% +43.32% +0.98% +9.55% -13.21% +4.73% +24.55% -17.69% +5.77% -10.45% +1.90% +8.86% +282.55% +203.54% +652.38% -99.56% -8.52% -5.30% -7.55% n/a n/a n/a n/a n/a n/a n/a n/a
    Product Revenue 158M 141.99M 328.93M 170.3M 162.54M 138.46M 156.02M 149M 128.34M 140.57M 163.78M 172.72M 165.46M 147.46M 73.29M 80.94M 78.78M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Product Revenue Growth +11.27% -56.83% +93.15% +4.78% +17.39% -11.25% +4.71% +16.10% -8.71% -14.17% -5.18% +4.39% +12.20% +101.22% -9.45% +2.74% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Qelbree Revenue 77.55M 64.75M 133.81M 62.36M 59.4M 45.1M 46.35M 37.08M 30.98M 25.78M 23.61M 18.33M 11.1M 8.28M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Qelbree Revenue Growth +19.77% -51.61% +114.58% +4.99% +31.68% -2.69% +25.00% +19.70% +20.15% +9.18% +28.86% +65.11% +34.00% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Royalty, License And Other Revenue Revenue 7.46M 7.84M 18.73M 5.39M 5.79M 15.99M 19.6M 20.63M 19.32M 34.79M 57.19M 69.6M 71.6M 62.83M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Royalty, License And Other Revenue Revenue Growth -4.82% -58.17% +247.76% -6.91% -63.81% -18.43% -4.96% +6.76% -44.47% -39.17% -17.83% -2.80% +13.96% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Trokendi Xr Revenue 11.19M 12.8M 31.89M 15.32M 17.09M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Trokendi Xr Revenue Growth -12.56% -59.86% +108.21% -10.35% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

    Operating Expense Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
    Selling, General, and Administrative Revenue 94.55M 89.94M 79.41M 69.75M 85.9M 86.52M 81.28M 82.7M 86.78M 85.6M 73.97M 112.31M 100.48M 90.46M 101.73M 72.03M 69.53M 61.46M 56.5M 54.66M 48.1M 42.88M 35.73M 39.34M 39.78M 40.97M 42.05M 40.89M 40.1M 36.85M 33.76M 40.83M 35.08M 28.24M 29.05M 25.68M 26.12M 25.16M 23.57M 22.9M 23.34M 19.4M
    Selling, General, and Administrative Revenue Growth +5.12% +13.27% +13.84% -18.80% -0.71% +6.44% -1.71% -4.70% +1.38% +15.72% -34.14% +11.78% +11.07% -11.08% +41.24% +3.59% +13.14% +8.77% +3.37% +13.63% +12.19% +20.01% -9.20% -1.09% -2.91% -2.57% +2.83% +1.98% +8.81% +9.14% -17.30% +16.38% +24.22% -2.81% +13.16% -1.71% +3.82% +6.76% +2.91% -1.87% +20.28% n/a
    Research and Development Revenue 21.61M 26.93M 28.05M 29.04M 25.58M 24.32M 22.74M 22.66M 24.38M 21.21M 17.77M 19.55M 16.39M 20.84M 21.08M 19.65M 15.46M 34.28M 17.94M 16.84M 22.25M 18.94M 19.79M 16.94M 16.97M 15.39M 29.84M 20.42M 20.04M 18.91M 16.17M 12.98M 10.82M 9.6M 13.25M 7.87M 11.11M 10.56M 9.45M 9.13M 6.88M 3.68M
    Research and Development Revenue Growth -19.73% -3.99% -3.41% +13.50% +5.20% +6.94% +0.38% -7.07% +14.93% +19.34% -9.10% +19.34% -21.37% -1.13% +7.25% +27.17% -54.92% +91.10% +6.53% -24.31% +17.48% -4.32% +16.82% -0.16% +10.24% -48.41% +46.12% +1.92% +5.98% +16.91% +24.60% +19.93% +12.73% -27.55% +68.43% -29.17% +5.18% +11.81% +3.47% +32.73% +86.75% n/a

    Add to Watchlist